Tirzepatide Telehealth

Tirzepatide Weight Loss: The Trial Evidence

The short version

Tirzepatide weight loss is the most-studied aspect of this medicine. Here is what the trials measured, in plain terms.

In the biggest trial (SURMOUNT-1), adults with obesity who did not have type 2 diabetes received once-weekly tirzepatide for 72 weeks (about 17 months). People on the highest dose — 15 mg — lost a mean of 20.9% of their body weight. People on placebo lost 3.1%. For a 100 kg person, that is roughly 20 kg versus 3 kg.

In a head-to-head trial (SURMOUNT-5), tirzepatide was compared directly against semaglutide in 751 adults with obesity but without diabetes, using the maximum dose each person could tolerate. Tirzepatide produced −20.2% body weight over 72 weeks; semaglutide produced −13.7%. The difference was statistically significant.

Stopping the medicine reverses much of the loss: a withdrawal study (SURMOUNT-4) found people who switched to placebo after losing about 20.9% during an open-label run-in regained most of that weight by 88 weeks, while those who kept taking tirzepatide lost another 5.5%. This is one of the most important practical findings: tirzepatide appears to work as a chronic therapy, not a short course.

Tirzepatide weight loss: SURMOUNT-1 results

SURMOUNT-1 was a 72-week phase 3 double-blind randomised controlled trial of 2,539 adults with obesity (BMI ≥30, or ≥27 with a weight-related complication) and without type 2 diabetes. Participants were randomised to once-weekly subcutaneous tirzepatide 5, 10, or 15 mg (after a 20-week stepwise escalation from 2.5 mg) or placebo.

Mean percentage weight change at 72 weeks [4]:

  • Tirzepatide 5 mg: −15.0%
  • Tirzepatide 10 mg: −19.5%
  • Tirzepatide 15 mg: −20.9%
  • Placebo: −3.1%

All tirzepatide doses were statistically superior to placebo (P<0.001). The most common adverse events were gastrointestinal (nausea, vomiting, diarrhoea, constipation) and were mostly mild to moderate, occurring primarily during dose escalation [4].

A post hoc analysis examined participants who were also using weight-inducing medications (roughly 17–20% of participants across SURMOUNT trials). Among them, percentage weight change versus placebo ranged from −13.3% (5 mg) to −21.3% (15 mg) at week 72 in SURMOUNT-1 — comparable to the primary results [20].

Tirzepatide weight loss vs semaglutide: SURMOUNT-5

SURMOUNT-5 is the first phase 3b head-to-head trial directly comparing tirzepatide with semaglutide for weight loss in 751 adults with obesity but without type 2 diabetes. Participants were randomised to the maximum tolerated dose of tirzepatide (10 or 15 mg) or the maximum tolerated dose of semaglutide (1.7 or 2.4 mg) once weekly for 72 weeks.

Least-squares mean weight change at week 72 [5]:

  • Tirzepatide (max tolerated dose): −20.2%
  • Semaglutide (max tolerated dose): −13.7%
  • Difference: −6.5 percentage points (P<0.001)

Tirzepatide also produced greater reductions in waist circumference and higher proportions of participants reaching ≥10%, ≥15%, ≥20%, and ≥25% weight loss thresholds [5].

This head-to-head result is important context for the tirzepatide vs semaglutide comparison that many readers search for: the two agents are both effective, but the trial evidence in obesity places tirzepatide above semaglutide in mean weight reduction.

Tirzepatide results: weight maintenance and regain after stopping (SURMOUNT-4)

SURMOUNT-4 tested what happens when people stop tirzepatide after achieving substantial weight loss. After a 36-week open-label run-in (mean loss: 20.9%), 670 participants were randomised to continue tirzepatide or switch to placebo for 52 more weeks.

Weight change from week 36 to week 88 [18]:

  • Continued tirzepatide: −5.5% (mean total loss from start: −25.3%)
  • Switched to placebo: +14.0% (mean total loss from start: −9.9%)
  • Difference: −19.4 percentage points (95% CI −21.2 to −17.7; P<0.001)

After stopping, cardiometabolic markers (blood pressure, lipids, glucose) also tracked back toward baseline, while those continuing tirzepatide continued to improve [21]. A pooled meta-analysis found that discontinuing GLP-1 and dual-agonist therapy leads to a mean regain of approximately 9.7 kg in the combined semaglutide/tirzepatide group [17].

Tirzepatide results from SURMOUNT-4 frame the therapy as chronic maintenance rather than a time-limited course — similar to how blood-pressure or cholesterol medicines work. This is one of the most clinically significant findings in the weight-management literature.

Tirzepatide dosage for weight loss — what the trials studied

In the SURMOUNT trials, the dosing protocol began at 2.5 mg once weekly for 4 weeks, then increased by 2.5 mg every 4 weeks as tolerated, with target maintenance doses of 5, 10, or 15 mg depending on the study arm. The once-weekly schedule is possible because of the approximately 5-day half-life that comes from the fatty-diacid albumin-binding modification [1].

The FDA-approved dosing schedule for chronic weight management follows the same stepwise titration as the trials. The full approved label and trial dosing context are covered on the dosage page.

A post hoc analysis of participants using concomitant weight-inducing medications (such as certain antidiabetic agents, antipsychotics, or corticosteroids) found that tirzepatide's weight-loss effect was preserved in this subgroup, with percentage weight reductions comparable to the primary efficacy results [20].

As this is an FDA-approved compound, the dosing information above is reported as labeled and trial-documented — not a personal recommendation. Prescribing decisions rest with a licensed clinician.